FK506, a secondary metabolite produced by Streptomyces, presents a novel antiviral activity against Orthopoxvirus infection in cell culture

Journal of Applied Microbiology

Volumn 100, Issue 6, 2006, Pages 1373-1380

  Reis, S A ^a   Moussatche N ^a   Damaso, C R A ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Antiviral compounds; Biotechnology; Cantagalo virus; FK506; Orthopoxvirus; Streptomyces metabolite; Vaccinia virus

Indexed keywords

BACTERIA; BIOMOLECULES; BIOSYNTHESIS; CELL CULTURE; PROTEINS; VIRUSES;

ANTIVIRAL ACTIVITIES; ANTIVIRAL COMPOUND; ANTIVIRALS; CANTAGALO VIRUS; CELL LINES; MACROLIDES; ORTHOPOXVIRUS; SECONDARY METABOLITES; STREPTOMYCES METABOLITE; VACCINIA VIRUS;

METABOLITES;

MACROLIDE; TACROLIMUS; VIRUS DNA; VIRUS PROTEIN;

BIOTECHNOLOGY; DNA; INHIBITION; VIRUS;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CERCOPITHECIDAE; DNA REPLICATION; DNA VIRUS; GRAM POSITIVE BACTERIUM; KIDNEY CELL; NONHUMAN; ORTHOPOXVIRUS; PROTEIN SYNTHESIS; SLOT BLOT HYBRIDIZATION; STREPTOMYCES; VACCINIA VIRUS; VIRUS INHIBITION; WESTERN BLOTTING;

ORTHOPOXVIRUS; POXVIRIDAE; STREPTOMYCES; STREPTOMYCES TSUKUBAENSIS; VACCINIA VIRUS;

EID: 33646540382     PISSN: 13645072     EISSN: 13652672     Source Type: Journal    
DOI: 10.1111/j.1365-2672.2006.02855.x     Document Type: Article

References (44)

1. Bertrand R. Solary E. O'Connor P. Kohn K.W. Pommier Y. 1994 Induction of a common pathway of apoptosis by staurosporine Exp Cell Res 211 314 321
2. Briggs C.J. Ott D.E. Coren L.V. Oroszlan S. Tozser J. 1999 Comparison of the effect of FK506 and cyclosporin A on virus production in H9 cells chronically and newly infected by HIV-1 Arch Virol 144 2151 2160
3. Castro A.P.V. Carvalho T.M.U. Moussatché N. Damaso C.R.A. 2003 Redistribution of cyclophilin A to the viral factories during vaccinia virus infection and its incorporation into mature particles J Virol 77 9052 9068
4. Damaso C.R.A. Esposito J.J. Condit R.C. Moussatché N. 2000 An emergent poxvirus from humans and cattle in Rio de Janeiro state: Cantagalo virus may derive from Brazilian smallpox vaccine Virology 277 439 449
5. Damaso C.R.A. Keller S.J. 1994 Cyclosporin A inhibits vaccinia virus replication in vitro Arch Virol 134 303 319
6. Damaso C.R.A. Moussatché N. 1998 Inhibition of vaccinia virus replication by cyclosporin A analogues correlates with their affinity for cellular cyclophilins J Gen Virol 79 339 346
7. Damaso C.R.A. Oliveira M.F. Massarani S.M. Moussatché N. 2002 Azathioprine inhibits vaccinia virus replication in both BSC-40 and Rag cell lines acting on different stages of virus cycle Virology 300 79 91
8. De Clercq E. Neyts J. 2004 Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections Rev Med Virol 14 289 300
9. Esposito J.J. Fenner F. 2001 Poxviruses In Fields Virology ed Knipe D.M. Howley P.M. Griffin D.E. Lamb R.A. Martin M.A. Roizman B. Straus S.E. pp 2885 2921 Philadelphia Lippincot Williams & Wilkins
10. Fung J.J. 2004 Tacrolimus and transplantation: a decade in review Transplantation 77 41 43
11. Hung J.J. Chung C.S. Chang W. 2002 Molecular chaperone Hsp90 is important for vaccinia virus growth in cells J Virol 76 1379 1390
12. Ikeda H. Fujiwara K. 1995 Cyclosporin A and FK-506 in inhibition of rat Ito cell activation in vitro Hepatology 21 1161 1166
13. Karpas A. Lowdell M. Jacobson S.K. Hill F. 1992 Inhibition of human immunodeficiency virus and growth of infected T cells by the immunosuppressive drugs cyclosporin A and FK506 Proc Natl Acad Sci USA 89 8351 8355
14. Kato S.E.M. Greco F.A.B. Damaso C.R.A. Condit R.C. Moussatché N. 2004 An alternative genetic method to test essentiality of vaccinia virus early genes J Virol Methods 115 31 40
15. Kino T. Hatanaka H. Miyata S. Noriaki I. 1987 FK-506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK-506 in vitro J Antibiot 40 1256 1265
16. Knight D.A. Hejmanowski A.Q. Dierksheide J.E. Williams J.W. Chong A.S. Waldman W.J. 2001 Inhibition of herpes simplex virus type 1 by the experimental immunosuppressive agent leflunomide Transplantation 71 170 174
17. Leao-Ferreira L.R. Paes-de-Carvalho R. de-Mello F.G. Moussatché N. 2002 Inhibition of vaccinia virus replication by adenosine in BSC-40 cells: involvement of A(2) receptor-mediated PKA activation Arch Virol 147 1407 1423
18. Ligon B.L. 2004 Monkeypox: a review of the history and emergence in the Western hemisphere Semin Pediatr Infect Dis 15 280 287
19. Luban J. Bossolt K.L. Franke E.K. Kalpana G.V. Goff S.P. 1993 Human immunodeficiency virus type 1 gag protein binds to cyclophilins A and B Cell 73 1067 1078
20. Masri M.A. 2003 The mosaic of immunosuppressive drugs Mol Immunol 39 1073 1077
21. Miyata Y. 2005 Hsp90 inhibitor geldanamycin and its derivatives as novel cancer chemotherapeutic agents Curr Pharm Des 11 1131 1138
22. Moore B.S. Kalaitzis J.A. Xiang L. 2005 Exploiting marine actinomycete biosynthetic pathways for drug discovery Antonie van Leeuwenhoek 87 49 57
23. Mortola E. Endo Y. Ohno K. Watari T. Tsujimoto H. Hasegawa A. 1998 The use of two immunosuppressive drugs, cyclosporin A and tacrolimus, to inhibit virus replication and apoptosis in cells infected with feline immunodeficiency virus Vet Res Commun 22 553 563
24. Moss B. 2001 Poxviridae: the viruses and their replication In Fields Virology ed Knipe D.M. Howley P.M. Griffin D.E. Lamb R.A. Martin M.A. Roizman B. Straus S.E. pp 2849 2883
25. Patel K. Piagentini M. Rascher A. Tian Z.Q. Buchanan G.O. Regentin R. Hu Z. Hutchinson C.R. et al. 2004 Engineered biosynthesis of geldanamycin analogs for Hsp90 inhibition Chem Biol 11 1625 1633
26. Reis S.A. Costa L.V. Cavalcanti E.D.C. Giambiagi-deMarval M. Semêdo L.T.A.S. Coelho R.R.R. Moussatché N. Damaso C.R.A. 2003 Protein synthesis inhibitory activity in culture filtrates from new strains of Streptomyces isolated from Brazilian tropical soils Lett Appl Microbiol 37 138 143
27. Sanglier J.J. Wellington E.M. Behal V. Fiedler H.P. Ellouz Ghorbel R. Finance C. Hacene M. Kamoun A. et al. 1993 Novel bioactive compounds from actinomycetes Res Microbiol 144 661 663
28. Schreiber S.L. Crabtree G.R. 1994 The mechanism of action of cyclosporin A and FK506 Immunol Today 13 136 141
29. Sekiguchi J. Shuman S. 1997 Novobiocin inhibits vaccinia virus replication by blocking virus assembly Virology 235 129 137
30. Shiraki K. Ishibashi M. Okuno T. Namazue J. Yamanishi K. Sonoda T. Takahashi M. 1991 Immunosuppressive dose of azathioprine inhibits replication of human cytomegalovirus in vitro Arch Virol 117 165 171
31. Siekierka J.J. Staruch M.J. Hung S.H. Sigal N.H. 1989 FK-506, a potent novel immunosuppressive agent, binds to cytosolic protein which is distinct from the cyclosporin A-binding protein cyclophilin J Immunol 143 1580 1583
32. Smee D.F. Bray M. Huggins J.W. 2001 Antiviral activity and mode of action studies of ribavirin and mycophenolic acid against orthopoxviruses in vitro Antivir Chem Chemother 12 327 335
33. Tali M. Bukovsky A. Kondo E. Rosenwirth B. Walsh C.T. Sodroski J. Göttlinger H.G. 1994 Functional association of cyclophilin A with HIV-1 virions Nature 372 363 365
34. Tamaoki T. Nakano H. 1990 Potent and specific inhibitors of protein kinase C of microbial origin Biotechnology 8 732 735
35. Thompson K.D. 1998 Antiviral activity of Viracea against acyclovir susceptible and acyclovir resistant strains of herpes simplex virus Antiviral Res 39 55 61
36. Tomono M. Toyoshima K. Ito M. Amano H. 1996 Calcineurin is essential for DNA synthesis in Swiss 3T3 fibroblasts Biochem J 317 675 680
37. Vanslyke J.K. Whitehead S.S. Wilson E.M. Hruby D.E. 1991 The multistep proteolytic maturation pathway utilized by vaccinia virus P4a protein: a degenerate conserved cleavage motif within core proteins Virology 183 467 478
38. Wallemacq P.E. Reding R. 1993 FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects Clin Chem 39 2219 2228
39. Weber T. Welzel K. Pelzer S. Vente A. Wohlleben W. 2003 Exploiting the genetic potential of polyketide producing streptomycetes J Biotechnol 106 221 232
40. Wehrli W. Staehelin M. 1971 Actions of the rifamycins Bacteriol Rev 35 290 309
41. Whitehead S.S. Hruby D.E. 1994 Differential utilization of a conserved motif for the proteolytic maturation of vaccinia virus proteins Virology 200 154 161
42. Wollenberg A. Engler R. 2004 Smallpox, vaccination and adverse reactions to smallpox vaccine Curr Opin Allergy Clin Immunol 4 271 275
43. Yokomizo K. Miyamoto Y. Nagao K. Kumagae E. Habib E.S. Suzuki K. Harada S. Uyeda M. 1998 Fattiviracin A1, a novel antiviral agent produced by Streptomyces microflavus strain No. 2445. II. Biological properties J Antibiot 51 1035 1039
44. Yorgin P.D. Hartson S.D. Fellah A.M. Scroggins B.T. Huang W. Katsanis E. Couchman J.M. Matts R.L. et al. 2000 Effects of geldanamycin, a heat-shock protein 90-binding agent, on T cell function and T cell nonreceptor protein tyrosine kinases J Immunol 164 2915 2923